Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neuropace, Inc. - Common Stock (NQ:NPCE)

8.560 -0.470 (-5.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neuropace, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Dow Jumps Over 300 Points; S&P 500 Rises 1.5%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Friday. The Dow traded up 1.03% to 33,343.73 while the NASDAQ rose 1.92% to 11,682.86. The S&P... 
Via Benzinga
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland. 
Via Benzinga
NeuroPace Earnings Preview
 
Via Benzinga
NeuroPace: Q2 Earnings Insights
  NeuroPace (NASDAQ:NPCE) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Nasdaq Up 150 Points; Crude Oil Rises 1%
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Friday. The Dow traded up 0.59% to 33,197.08 while the NASDAQ rose 1.32% to 11,614.60. The S&P... 
Via Benzinga
NeuroPace Reports Fourth Quarter & Full Year 2022 Financial Results
From NeuroPace, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
 
Via Benzinga
NeuroPace to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
From NeuroPace, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints Dr. Uri Geiger to Board of Directors
From NeuroPace, Inc.
Via GlobeNewswire
Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
NeuroPace to Present at the 41st Annual J.P. Morgan Healthcare Conference
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Feasibility Study of Its RNS System for Lennox-Gastaut Syndrome Now Underway
From NeuroPace, Inc.
Via Business Wire
$10 Million Bet On Canoo? Check Out These 3 Stocks Under $3 Insiders Are Buying
The Nasdaq Composite closed higher by more than 100 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  Monday saw 33 companies set new 52-week lows. 
Via Benzinga
NeuroPace Reports Third Quarter 2022 Financial Results and Provides a Business Update
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Present at the 4th Annual Wolfe Research Healthcare Conference
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Report Third Quarter 2022 Financial Results on November 8, 2022
From NeuroPace, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 120 companies set new 52-week lows. 
Via Benzinga
NeuroPace Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy (IGE)
From NeuroPace, Inc.
Via Business Wire
NeuroPace's Return On Capital Employed Insights
NeuroPace (NASDAQ:NPCE) brought in sales totaling $10.20 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 10.72%, resulting in a loss of $12.69 million. 
Via Benzinga
5 Analysts Have This to Say About NeuroPace
Over the past 3 months, 5 analysts have published their opinion on NeuroPace (NASDAQ:NPCE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Recap: NeuroPace Q1 Earnings
NeuroPace (NASDAQ:NPCE) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings NeuroPace missed estimated earnings... 
Via Benzinga
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.